273 related articles for article (PubMed ID: 21060682)
1. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.
Pungaliya PP; Bai Y; Lipinski K; Anand VS; Sen S; Brown EL; Bates B; Reinhart PH; West AB; Hirst WD; Braithwaite SP
PLoS One; 2010 Oct; 5(10):e13672. PubMed ID: 21060682
[TBL] [Abstract][Full Text] [Related]
2. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
[TBL] [Abstract][Full Text] [Related]
3. Identification of the autophosphorylation sites of LRRK2.
Kamikawaji S; Ito G; Iwatsubo T
Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
[TBL] [Abstract][Full Text] [Related]
4. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
Liu Z; West AB
Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR
PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
8. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
Ho DH; Kim H; Kim J; Sim H; Ahn H; Kim J; Seo H; Chung KC; Park BJ; Son I; Seol W
Mol Brain; 2015 Sep; 8():54. PubMed ID: 26384650
[TBL] [Abstract][Full Text] [Related]
9. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
[TBL] [Abstract][Full Text] [Related]
10. Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity.
Zach S; Felk S; Gillardon F
PLoS One; 2010 Oct; 5(10):e13191. PubMed ID: 20949042
[TBL] [Abstract][Full Text] [Related]
11. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
[TBL] [Abstract][Full Text] [Related]
12. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
13. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.
Liu M; Kang S; Ray S; Jackson J; Zaitsev AD; Gerber SA; Cuny GD; Glicksman MA
Biochemistry; 2011 Nov; 50(43):9399-408. PubMed ID: 21961647
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers.
Civiero L; Vancraenenbroeck R; Belluzzi E; Beilina A; Lobbestael E; Reyniers L; Gao F; Micetic I; De Maeyer M; Bubacco L; Baekelandt V; Cookson MR; Greggio E; Taymans JM
PLoS One; 2012; 7(8):e43472. PubMed ID: 22952686
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
16. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
[TBL] [Abstract][Full Text] [Related]
17. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
18. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
Anand VS; Reichling LJ; Lipinski K; Stochaj W; Duan W; Kelleher K; Pungaliya P; Brown EL; Reinhart PH; Somberg R; Hirst WD; Riddle SM; Braithwaite SP
FEBS J; 2009 Jan; 276(2):466-78. PubMed ID: 19076219
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 autophosphorylation enhances its GTPase activity.
Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB
FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
